Position of the Transparency Council – Rythmodan (disopyramide)
At its meeting on 20 January 2025, the Transparency Council adopted position No. 11/2025 on the appropriateness of issuing approvals for reimbursement of the drug Rythmodan (disopyramide) for the indications: supraventricular arrhythmias, ventricular arrhythmias, hypertrophic cardiomyopathy with left ventricular outflow tract narrowing.
Publication of the position >>